"God" drug market boiling pharmaceutical companies will usher in a golden period of development

Data show that in China, there are 2.8 million cancer deaths each year. When we don't want to talk about cancer drugs, venture capital is building a booming market, especially in 2016.the booming "God" drug market
just a month ago, a company that produces only one cancer drug went public on the GEM. In Beida Pharmaceuticals' prospecto, 5,000 yuan a box of cancer drugs accounts for almost 100% of its total revenue.
the first half of 2016,
's sales revenue reached 518 million yuan,
's net profit was 212 million yuan,
's net profit margin was as high as 40.92 percent, and
's total production costs amounted to 42.8148 million yuan
costs accounted for only 8.26 percent of sales.
this is the impressively strong blood-building capacity of the cancer market.
cancer drug companies in the year-on-year surge in patients and high medical expenses, even if the capital winter, still like a flat green cloud.
, one of the largest anti-tumor drug companies in China, Hengrui Pharmaceuticals' share price has risen more than 60 times since 2004, and its total market value has grown from more than 2 billion to more than 100 billion today.
November 29th, Cyntharma Biopharma completed a $260 million round of D-round financing, and the horns of the IPO were deafening.
in early 2016, the cancer drug company Baiji Shenzhou became the first Chinese company to go to the U.S. for an IPO, which, bizarrely, didn't even make the product, but had a market capitalization of $720 million on its first day of trading.
, just five years after its founding, the state is home to a number of top domestic and foreign investment institutions, including High Capital, CITIC Industries, As well as Fidelity Management and Research Company, T. Rowe Price and Associates, Rock Springs Capital Management, Boxer Capital of Tavistock Sciences and others.
the 700m market capitalisation estimates not the size of Baiji Shenzhou's revenues, but its scientific capabilities and future commercial potential.
the snowballs of cancer-fighting drug companies are rolling bigger and bigger, with investors helping to step on the wind and fire wheel in the cold winter.
Some analysts say that the cancer industry has great prospects, especially for companies with clear product development, once the relevant products through clinical trials, the future will be repeatedly active, from the market performance, the funds are very much in love with "anti-cancer patents."climb the ladder, salty fish turn over
However, through clinical trials, access to qualifications, to become anti-cancer drug enterprises to achieve metamorphosis of the ladder entrance.
According to Zhang Hongjun, director of beijing Guodi radish thioelectrin science research institute revealed: "The drug is just needed, the capital side needs the enterprise to become a drug, they have seen the anti-cancer business opportunities, but the capital side likes to be able to see the benefits, so the drug will minimize the risk." The valuation of an anticancer drug company doubles when its drug passes its qualifications. "
it is worth noting that the biopharmaceutical industry's capital presence is currently small relative to the Internet industry. In the first half of 2016, China's biotechnology/health care industry invested 4,181 million yuan, while the Internet industry invested 21.941 billion yuan, less than a fifth of the latter, according to Qingke data.
But in the U.S. capital market, there are companies that can understand such companies and are willing to give such companies high valuation funds, in the past three years, the largest number of U.S. IPOs are not IT and Internet companies, but biological and pharmaceutical companies, and many are such a small revenue scale, but achieved some research results, things sound cool companies, for such companies, the U.S. capital market has a mature system.
according to Zhang Hongjun, its research and development of radish thioelectrin anti-cancer products will also be clinical next year, after which it will be approved as a drug, estimated to be in 2019. The persuasive power of capital will then be fully increased.
Over the past five years, 70 new cancer drugs have been approved in more than 20 different tumor types, most of which are sold in a limited number of countries or approved by drug regulators but are not accepted by medical cost control agencies.
in this industry chain, involving the government, hospitals/doctors, pharmaceutical companies, and finally patients, the core of the industry is hospitals/doctors. Hospitals are a piece of cake that everyone is grabbing because of their large size, so there is order chaos, but once the product enters a hospital, the commercial value of the company may be greatly increased.
hospitals in the entry threshold there are a few considerations: First, first, look at the scientific research team; Second, the product effect; Third, prices are unacceptable to ordinary people.
Zhang Hongjun explained: "For example, a cancer hospital in Beijing, their nutrition department director looked at our things very interested, the first step to establish a cognition, understand later we provided some samples, they gave the patient after use, feel good, and then put forward the second step, let's temporarily sell in his pharmacy." In the process of temporary sale, there are patients we recommend the past to buy, if taken well, early next year we are ready to bid, directly into the hospital system, the doctor directly open nutrition medicine. The business opportunities here are very great. According2015 data from the
, 2015, 8 people were diagnosed with cancer and 5.2 died every minute. These shocking data hooks are the result of an impending cancer blowout (a large-scale outbreak) in 2030. Strong market demand means the emergence of opportunities.
the world is clinically studied but not yet approved for the market of anti-cancer drugs, the total number of genetic drugs about 800, these anti-cancer drugs will be the human 20 to 50 years to fight cancer new weapons.
as one of them, Zhang Hongjun told reporters: "To be precise, we are the world's leading, because we mainly solved the two technical core, the first problem is purity, achieved 99.877 percent;" Second, we are the only research and development organization in the world that can address the stability of radish thiocin. "For Zhang Hongjun, although there are 6 patents in hand, but the radish thiocin industry is just beginning, the public awareness there are still some problems. Although the efficacy of the substance was confirmed as early as 1948 by professors at Hawkins University in the United States, even many doctors now have a very limited understanding of the market and an education time is needed.
entrepreneurs, there are good products and services, there is no need to capital winter scared. From an investor's point of view, they even prefer a cold winter of capital, because in this case they can find some good investment projects. The industries chosen by entrepreneurs, the competitiveness of startups themselves, and profitability are highly valued.
start-up must have the ability to make blood, can not let financing determine life and death, stable and healthy profitability will determine how long your company can go. So, when capital bets on cancer drugs, a high-barrier, high-regulated investment area, can the higher profit curve push down the cancer-worsening curve? After all, the lower the incidence, for you and I are a great blessing. (Pizza Hut)